{"id":66933,"date":"2026-06-01T14:18:27","date_gmt":"2026-06-01T06:18:27","guid":{"rendered":"https:\/\/flcube.com\/?p=66933"},"modified":"2026-06-01T14:18:28","modified_gmt":"2026-06-01T06:18:28","slug":"bristol-myers-squibbs-mezigdomide-kd-combination-shows-52-risk-reduction-in-relapsed-multiple-myeloma-in-phase-3-successor-2-trial","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=66933","title":{"rendered":"Bristol-Myers Squibb&#8217;s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Bristol-Myers Squibb (BMS; <a href=\"https:\/\/www.google.com\/finance\/quote\/BMY:NYSE\">NYSE: BMY<\/a>)<\/strong> announced <strong>positive late-breaking results<\/strong> from the <strong>Phase 3 SUCCESSOR-2 trial (NCT05552976)<\/strong> of <strong>mezigdomide<\/strong>, an oral <strong>CELMoD (cereblon E3 ligase modulation) agent<\/strong>, in combination with <strong>carfilzomib and dexamethasone (MeziKd)<\/strong> versus <strong>carfilzomib and dexamethasone alone (Kd)<\/strong> in patients with <strong>relapsed or refractory multiple myeloma (RRMM)<\/strong> at the <strong>2026 American Society of Clinical Oncology (ASCO) Annual Meeting<\/strong>. The trial demonstrated a <strong>clinically meaningful and statistically significant improvement in progression-free survival (PFS)<\/strong>, with MeziKd reducing the risk of disease progression or death by <strong>52% compared to Kd<\/strong> (HR: 0.48; p&lt;0.0001).<\/p>\n\n\n\n<h2 id=\"h-clinical-trial-results\" class=\"wp-block-heading\">Clinical Trial Results<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (MeziKd)<\/th><th>Comparator (Kd)<\/th><th>Benefit<\/th><\/tr><\/thead><tbody><tr><td><strong>Primary Endpoint<\/strong><\/td><td>Progression-Free Survival (PFS)<\/td><td>Kd alone<\/td><td><strong>52% risk reduction<\/strong> (HR: 0.48; p&lt;0.0001)<\/td><\/tr><tr><td><strong>Median PFS<\/strong><\/td><td>18 months<\/td><td>8.3 months<\/td><td><strong>9.7-month improvement<\/strong><\/td><\/tr><tr><td><strong>Patient Population<\/strong><\/td><td>Relapsed\/refractory multiple myeloma<\/td><td>Same population<\/td><td>Heavily pre-treated cohort<\/td><\/tr><tr><td><strong>Confidence Interval<\/strong><\/td><td>95% CI reported<\/td><td>Standard statistical analysis<\/td><td>Highly statistically significant<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Mezigdomide<\/strong> \u2013 oral <strong>CELMoD agent<\/strong> from BMS&#8217; targeted protein degradation platform<\/li>\n\n\n\n<li><strong>Target Optimization:<\/strong> Specifically engineered for <strong>maximal and rapid degradation of Ikaros and Aiolos target proteins<\/strong><\/li>\n\n\n\n<li><strong>Dual Mechanism:<\/strong> Simultaneously enhances <strong>multiple myeloma cell killing<\/strong> and <strong>immune stimulation<\/strong><\/li>\n\n\n\n<li><strong>Platform Advantage:<\/strong> Represents next-generation cereblon modulator with improved potency over earlier immunomodulatory drugs (IMiDs)<\/li>\n\n\n\n<li><strong>Oral Administration:<\/strong> Convenient daily dosing compatible with standard myeloma treatment regimens<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-disease-context-amp-unmet-need\" class=\"wp-block-heading\">Disease Context &amp; Unmet Need<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Relapsed or refractory multiple myeloma (RRMM)<\/strong> remains incurable despite recent therapeutic advances, with most patients experiencing <strong>disease progression within 1\u20132 years<\/strong> of initial treatment. The <strong>Kd regimen (carfilzomib + dexamethasone)<\/strong> represents a current standard of care for relapsed disease, but outcomes remain suboptimal, particularly in patients with high-risk cytogenetics or multiple prior lines of therapy.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The SUCCESSOR-2 results position mezigdomide as a potential new backbone for RRMM treatment:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Substantial PFS benefit<\/strong>: Nearly doubling median progression-free survival from 8.3 to 18 months<\/li>\n\n\n\n<li><strong>Novel mechanism<\/strong>: First CELMoD agent to demonstrate superiority over established proteasome inhibitor combinations<\/li>\n\n\n\n<li><strong>Platform validation<\/strong>: Confirms BMS&#8217; leadership in targeted protein degradation therapeutics<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">&#8220;This is a transformative result for patients with relapsed multiple myeloma who desperately need more effective treatment options,&#8221; said Dr. Samit Hirawat, Chief Medical Officer, Global Drug Development at Bristol-Myers Squibb. &#8220;Mezigdomide&#8217;s ability to significantly extend progression-free survival while maintaining a manageable safety profile could establish a new standard of care in this difficult-to-treat population.&#8221;<\/p>\n\n\n\n<h2 id=\"h-commercial-and-strategic-implications\" class=\"wp-block-heading\">Commercial and Strategic Implications<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The RRMM market represents a significant commercial opportunity for BMS:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Addressable Population:<\/strong> Approximately <strong>30,000\u201335,000 relapsed\/refractory myeloma patients annually in the U.S.<\/strong><\/li>\n\n\n\n<li><strong>Franchise Expansion:<\/strong> Complements BMS&#8217; existing myeloma portfolio including <strong>pomalidomide (POMALYST)<\/strong> and <strong>belantamab mafodotin<\/strong><\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> Challenges emerging CELMoD competitors and established standards like <strong>daratumumab-based regimens<\/strong><\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts estimate peak annual sales of <strong>$1.5\u20132.5 billion<\/strong> for mezigdomide in RRMM<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">BMS plans to submit regulatory applications to global health authorities in <strong>Q3 2026<\/strong>, with potential accelerated approval pathways given the magnitude of clinical benefit demonstrated.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding clinical trial results, regulatory submissions, and commercial opportunities for mezigdomide. Actual outcomes may vary based on regulatory decisions, competitive developments, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[106,429,428,17,849],"class_list":["post-66933","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-academic-conference","tag-bms","tag-bristol-myers-squibb","tag-clinical-trial-results","tag-nyse-bmy"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Bristol-Myers Squibb&#039;s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of mezigdomide, an oral CELMoD (cereblon E3 ligase modulation) agent, in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS), with MeziKd reducing the risk of disease progression or death by 52% compared to Kd (HR: 0.48; p&lt;0.0001).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=66933\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Bristol-Myers Squibb&#039;s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial\" \/>\n<meta property=\"og:description\" content=\"Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of mezigdomide, an oral CELMoD (cereblon E3 ligase modulation) agent, in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS), with MeziKd reducing the risk of disease progression or death by 52% compared to Kd (HR: 0.48; p&lt;0.0001).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=66933\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-01T06:18:27+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-01T06:18:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66933#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66933\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Bristol-Myers Squibb&#8217;s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial\",\"datePublished\":\"2026-06-01T06:18:27+00:00\",\"dateModified\":\"2026-06-01T06:18:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66933\"},\"wordCount\":506,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Academic conference\",\"BMS\",\"Bristol-Myers Squibb\",\"Clinical trial results\",\"NYSE: BMY\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66933#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66933\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=66933\",\"name\":\"Bristol-Myers Squibb's Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-01T06:18:27+00:00\",\"dateModified\":\"2026-06-01T06:18:28+00:00\",\"description\":\"Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of mezigdomide, an oral CELMoD (cereblon E3 ligase modulation) agent, in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS), with MeziKd reducing the risk of disease progression or death by 52% compared to Kd (HR: 0.48; p&lt;0.0001).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66933#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=66933\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=66933#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Bristol-Myers Squibb&#8217;s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Bristol-Myers Squibb's Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial - Insight, China&#039;s Pharmaceutical Industry","description":"Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of mezigdomide, an oral CELMoD (cereblon E3 ligase modulation) agent, in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS), with MeziKd reducing the risk of disease progression or death by 52% compared to Kd (HR: 0.48; p&lt;0.0001).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=66933","og_locale":"en_US","og_type":"article","og_title":"Bristol-Myers Squibb's Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial","og_description":"Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of mezigdomide, an oral CELMoD (cereblon E3 ligase modulation) agent, in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS), with MeziKd reducing the risk of disease progression or death by 52% compared to Kd (HR: 0.48; p&lt;0.0001).","og_url":"https:\/\/flcube.com\/?p=66933","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-01T06:18:27+00:00","article_modified_time":"2026-06-01T06:18:28+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=66933#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=66933"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Bristol-Myers Squibb&#8217;s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial","datePublished":"2026-06-01T06:18:27+00:00","dateModified":"2026-06-01T06:18:28+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=66933"},"wordCount":506,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Academic conference","BMS","Bristol-Myers Squibb","Clinical trial results","NYSE: BMY"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=66933#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=66933","url":"https:\/\/flcube.com\/?p=66933","name":"Bristol-Myers Squibb's Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-01T06:18:27+00:00","dateModified":"2026-06-01T06:18:28+00:00","description":"Bristol-Myers Squibb (BMS; NYSE: BMY) announced positive late-breaking results from the Phase 3 SUCCESSOR-2 trial (NCT05552976) of mezigdomide, an oral CELMoD (cereblon E3 ligase modulation) agent, in combination with carfilzomib and dexamethasone (MeziKd) versus carfilzomib and dexamethasone alone (Kd) in patients with relapsed or refractory multiple myeloma (RRMM) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The trial demonstrated a clinically meaningful and statistically significant improvement in progression-free survival (PFS), with MeziKd reducing the risk of disease progression or death by 52% compared to Kd (HR: 0.48; p&lt;0.0001).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=66933#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=66933"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=66933#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Bristol-Myers Squibb&#8217;s Mezigdomide-Kd Combination Shows 52% Risk Reduction in Relapsed Multiple Myeloma in Phase 3 SUCCESSOR-2 Trial"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66933","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=66933"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66933\/revisions"}],"predecessor-version":[{"id":66934,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/66933\/revisions\/66934"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=66933"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=66933"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=66933"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}